Triple negative breast cancer

Meet our team

Eveline Baelen

Senior Therapeutic Specialist Belgium North

Carine Smet

Senior Therapeutic Specialist Belgium Center

Jean-Pol Guillaume

Senior Therapeutic Specialist Belgium South

Annelies Laeremans

Associate Director Medical Affairs Oncology
Request for Medical Information

Ioana Stoian

Senior Manager Medical Affairs Oncology

Stay informed about the latest news, congresses and educational events and resources

  1. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938-48
  2. Lebert JM, Lester R, Powell E, Seal M, Mccarthy J. Advances in the systemic treatment of triple-negative breast cancer. Curr. Oncol. 2018;25(Suppl) 1):S142-S50
  3. Sharma P. Biology and Management of patients with triple-Negative Breast Cancer. Oncologist. 2016;21(9):1050-62
  4. American Cancer Society. Accessed 31 May 2022
  5. Lee A, Djamgoz MBA. Triple negative breast cancer : Emerging therapeutic modalities and novel combination therapies. Cancer Treat Rev. 2018;62:110-22 
  6. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative and HER2-negative invasive breast cancer, the so-called triple negative phenotype: a population-based study from the California cancer registry. 2007;109(9):172-8.
  7. Belgian Cancer Registry, facts and figures for 2019.
  8. Linda Lindstrom et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor 2 are unstable throughout tumor progression. J of Clin Oncol 2012;30(21):2601-8.
  9. Sung et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA CANCER J CLIN 2021;71:209-249
  10. Seah DSE et al. Use and Duration of Chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy. J Natl Compr Canc Netw. 2014;12(1):71-80.
  11. T Grinda et al. Evolution of overall survival and receipt of new therapies by subtype among 20446 metastatic breast cancer patients in the 2008-2017 ESME cohort. ESMO Open Cancer Horizons 2021
  12. American Cancer Society. Facts and figures 2019-2020. Accessed June 2022
  13. accessed June 2022